Compare MDRR & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDRR | IRIX |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 18.2M |
| IPO Year | N/A | 1996 |
| Metric | MDRR | IRIX |
|---|---|---|
| Price | $11.52 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.9K | ★ 44.4K |
| Earning Date | 03-02-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,593,000.00 |
| Revenue This Year | N/A | $3.07 |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.47 | $0.87 |
| 52 Week High | $14.52 | $1.65 |
| Indicator | MDRR | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 49.75 |
| Support Level | $11.48 | $1.01 |
| Resistance Level | $12.20 | $1.18 |
| Average True Range (ATR) | 0.32 | 0.04 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 46.77 | 22.22 |
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.